Limits...
Attenuation of lung inflammation and fibrosis in CD69-deficient mice after intratracheal bleomycin.

Yamauchi K, Kasuya Y, Kuroda F, Tanaka K, Tsuyusaki J, Ishizaki S, Matsunaga H, Iwamura C, Nakayama T, Tatsumi K - Respir. Res. (2011)

Bottom Line: Cluster of differentiation 69 (CD69), an early activation marker antigen on T and B cells, is also expressed on activated macrophages and neutrophils, suggesting that CD69 may play a role in inflammatory diseases.Lung inflammation in the acute phase (7 dpi) was investigated by differential cell counts and cytokine array analyses of bronchoalveolar lavage fluid.In addition, lung fibrotic changes were evaluated at 14 dpi by histopathology and collagen assays.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.

ABSTRACT

Background: Cluster of differentiation 69 (CD69), an early activation marker antigen on T and B cells, is also expressed on activated macrophages and neutrophils, suggesting that CD69 may play a role in inflammatory diseases. To determine the effect of CD69 deficiency on bleomycin(BLM)-induced lung injury, we evaluated the inflammatory response following intratracheal BLM administration and the subsequent fibrotic changes in wild type (WT) and CD69-deficient (CD69-/-) mice.

Methods: The mice received a single dose of 3 mg/kg body weight of BLM and were sacrificed at 7 or 14 days post-instillation (dpi). Lung inflammation in the acute phase (7 dpi) was investigated by differential cell counts and cytokine array analyses of bronchoalveolar lavage fluid. In addition, lung fibrotic changes were evaluated at 14 dpi by histopathology and collagen assays. We also used reverse transcription polymerase chain reaction to measure the mRNA expression level of transforming growth factor β1 (TGF-β1) in the lungs of BLM-treated mice.

Results: CD69-/- mice exhibited less lung damage than WT mice, as shown by reductions in the following indices: (1) loss of body weight, (2) wet/dry ratio of lung, (3) cytokine levels in BALF, (4) histological evidence of lung injury, (5) lung collagen deposition, and (6) TGF-β1 mRNA expression in the lung.

Conclusion: The present study clearly demonstrates that CD69 plays an important role in the progression of lung injury induced by BLM.

Show MeSH

Related in: MedlinePlus

Effect of bleomycin treatment on body weight in wild-type and CD69-deficient mice. Time course of changes in body weight after bleomycin (BLM) treatment in wild-type (WT) (n = 8) and cluster of differentiation 69 (CD69)-deficient (CD69-/-) mice (n = 6). Results are expressed as the mean (SEM), *P < 0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3198935&req=5

Figure 1: Effect of bleomycin treatment on body weight in wild-type and CD69-deficient mice. Time course of changes in body weight after bleomycin (BLM) treatment in wild-type (WT) (n = 8) and cluster of differentiation 69 (CD69)-deficient (CD69-/-) mice (n = 6). Results are expressed as the mean (SEM), *P < 0.05.

Mentions: To determine the biological significance of CD69 deficiency after acute lung injury, we tracked weight changes following BLM exposure. WT mice showed typical and persistent body weight loss after BLM exposure. In contrast, the CD69-/- mice transiently lost body weight after BLM exposure but underwent steady weight gain thereafter. Between the two groups, a marked difference was observed (Figure 1). In mice injected with PBS, the mice body showed daily weight gain without any loss (data not shown).


Attenuation of lung inflammation and fibrosis in CD69-deficient mice after intratracheal bleomycin.

Yamauchi K, Kasuya Y, Kuroda F, Tanaka K, Tsuyusaki J, Ishizaki S, Matsunaga H, Iwamura C, Nakayama T, Tatsumi K - Respir. Res. (2011)

Effect of bleomycin treatment on body weight in wild-type and CD69-deficient mice. Time course of changes in body weight after bleomycin (BLM) treatment in wild-type (WT) (n = 8) and cluster of differentiation 69 (CD69)-deficient (CD69-/-) mice (n = 6). Results are expressed as the mean (SEM), *P < 0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3198935&req=5

Figure 1: Effect of bleomycin treatment on body weight in wild-type and CD69-deficient mice. Time course of changes in body weight after bleomycin (BLM) treatment in wild-type (WT) (n = 8) and cluster of differentiation 69 (CD69)-deficient (CD69-/-) mice (n = 6). Results are expressed as the mean (SEM), *P < 0.05.
Mentions: To determine the biological significance of CD69 deficiency after acute lung injury, we tracked weight changes following BLM exposure. WT mice showed typical and persistent body weight loss after BLM exposure. In contrast, the CD69-/- mice transiently lost body weight after BLM exposure but underwent steady weight gain thereafter. Between the two groups, a marked difference was observed (Figure 1). In mice injected with PBS, the mice body showed daily weight gain without any loss (data not shown).

Bottom Line: Cluster of differentiation 69 (CD69), an early activation marker antigen on T and B cells, is also expressed on activated macrophages and neutrophils, suggesting that CD69 may play a role in inflammatory diseases.Lung inflammation in the acute phase (7 dpi) was investigated by differential cell counts and cytokine array analyses of bronchoalveolar lavage fluid.In addition, lung fibrotic changes were evaluated at 14 dpi by histopathology and collagen assays.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.

ABSTRACT

Background: Cluster of differentiation 69 (CD69), an early activation marker antigen on T and B cells, is also expressed on activated macrophages and neutrophils, suggesting that CD69 may play a role in inflammatory diseases. To determine the effect of CD69 deficiency on bleomycin(BLM)-induced lung injury, we evaluated the inflammatory response following intratracheal BLM administration and the subsequent fibrotic changes in wild type (WT) and CD69-deficient (CD69-/-) mice.

Methods: The mice received a single dose of 3 mg/kg body weight of BLM and were sacrificed at 7 or 14 days post-instillation (dpi). Lung inflammation in the acute phase (7 dpi) was investigated by differential cell counts and cytokine array analyses of bronchoalveolar lavage fluid. In addition, lung fibrotic changes were evaluated at 14 dpi by histopathology and collagen assays. We also used reverse transcription polymerase chain reaction to measure the mRNA expression level of transforming growth factor β1 (TGF-β1) in the lungs of BLM-treated mice.

Results: CD69-/- mice exhibited less lung damage than WT mice, as shown by reductions in the following indices: (1) loss of body weight, (2) wet/dry ratio of lung, (3) cytokine levels in BALF, (4) histological evidence of lung injury, (5) lung collagen deposition, and (6) TGF-β1 mRNA expression in the lung.

Conclusion: The present study clearly demonstrates that CD69 plays an important role in the progression of lung injury induced by BLM.

Show MeSH
Related in: MedlinePlus